SeaStar Medical and AREVA Institute Collaborate on Innovative Burn Treatment Research with DoD Grant
TL;DR
SeaStar Medical's SCD therapy, backed by a $2 million DoD grant, offers a groundbreaking advantage in treating severe burns and infections by reducing hyperinflammation and improving survival rates.
The SCD therapy works by modifying the immune response outside the body, neutralizing overactive immune cells to reduce hyperinflammation, then reintroducing them in a less active state.
This innovative therapy promises to make tomorrow better by potentially saving lives and reducing the need for lifelong dialysis in patients with severe trauma and infections.
SeaStar Medical's device, already cutting pediatric AKI mortality rates by half, now explores treating severe burns, showcasing its broad potential in acute and chronic diseases.
Found this article helpful?
Share it with your network and spread the knowledge!
The collaboration between SeaStar Medical and the Autonomous Reanimation and Evacuation (AREVA) Research Institute marks a significant advancement in the treatment of severe burns, inhalation injuries, and septicemia. Funded by a Department of Defense (DoD) grant, this partnership focuses on exploring the potential of SeaStar Medical's Selective Cytopheretic Device (SCD) therapy to mitigate hyperinflammation, a common and deadly complication of these conditions.
The DoD grant, awarded to AREVA as part of the 2024 Military Burn Research Program (MBRP), supports a three-year study beginning in July 2025. With over $2 million in funding, the research aims to evaluate the SCD therapy's effectiveness in reducing hyperinflammation, thereby improving survival rates and recovery outcomes for both military and civilian patients. The SCD therapy, used alongside continuous renal replacement therapy (CRRT), is designed to support organ recovery, potentially reducing the need for lifelong dialysis and saving lives.
Dr. Andriy Batchinsky, principal investigator and founder of AREVA, highlighted the potential impact of this research, stating it could be one of the most significant in his 25-year career. The Geneva Foundation will provide administrative and operational support to ensure the study's success at the AREVA Institute in San Antonio, Texas.
SeaStar Medical's SCD therapy has already shown promise in treating pediatric acute kidney injury (AKI), with FDA approval in February 2024. Clinical trials demonstrated a 50% reduction in mortality rates and decreased dialysis time for patients. The company is currently conducting a trial for adult AKI, with 119 patients enrolled and a target of 200.
This research not only represents a potential breakthrough in treating severe burns and related conditions but also underscores the SCD therapy's broader applications in acute and chronic kidney and cardiovascular diseases. With its organ and disease-agnostic approach, SeaStar Medical's technology offers hope for patients with limited treatment options, marking a significant step forward in medical science and patient care.
Curated from NewMediaWire
